Approaches to treat cancer with therapeutic vaccination have made significant progress. In
order to induce efficient antitumor immunity, a vaccine should target and activate antigen-
presenting cells, such as the dendritic cell, while delivering the tumor-derived antigen of
choice. Conjugates of synthetic peptides and ligands of pattern-recognition receptors
(PRRs) combine these features and, given their synthetic nature, can be produced under
GMP conditions. Therefore, conjugation of antigenic peptides to potent PRR ligands is a …